PERCUTANEOUS RADIOFREQUENCY ABLATION FOR PRIMARY AND METASTATIC LIVER CANCERS BY AN EXPANDABLE ELECTRODE

• Published in: Kita Kantō igaku (The Kitakanto Medical Journal) Vol. 51; no. 2; pp. 129 - 134
• Main Authors: Nakajima, Hiroaki, Kuwano, Hiroyuki, Asao, Takayuki, Suzuki, Hideki, Mori, Masatomo, Shimura, Tatsuo, Ishijima, Hideyuki, Ohwada, Susumu, Takeichi, Takayuki, Sato, Ken, Kawate, Susumu, Kanda, Daisuke, Otsuka, Toshiyuki, Nomoto, Kenichi, Tomizawa, Naoki, Takagi, Hitoshi, Takayama, Hisashi, Aoki, Jun
• Format: Journal Article
• Language: English
• Published: The Kitakanto Medical Society 2001
• Subjects: Metastatic liver tumors; Percutaneous radiofrequency ablation; Primary liver tumor
• ISSN: 1343-2826; 1881-1191; 1881-1191
• DOI: 10.2974/kmj.51.129

Radiofrequency ablation (RFA) has recently begun being used against liver cancer. Subjects were 5 patients with hepatocellular carcinoma (HCC), 1 with cholangiocellular carcinoma, and 3 with metastatic liver cancer, 1 of whom was treated intraoperatively with RFA and 8 of whom were treated percutaneously. The patient with HCC was additionally treated by intraoperative RFA after percutaneous RFA. RFA was effective in 7 of 9 (77.8%) but not in 2 as determined by computed tomography and serum tumor markers. Post-RFA complication included slight side effects in liver function and 1 patient (11.1%) who had prolonged fever, local pain and right pleural effusion. One of the 7 treated effectively (14.3%) showed Post-REA recurrence. RFA is thus effective in feating liver cancer locally.